MONEY MASTER

Poseida Therapeutics (PSTX.US)   announced on Tuesday that it has entered into a definitive agreement to be acquired by   Roche Holdings   in a deal valued at approximately   $1.5 billion   on a fully diluted basis. Under the terms of the agreement,  Roche will launch a tender offer  to acquire all of Poseida’s outstanding shares for  $9 per share in cash.  Additionally, shareholders will receive a  non-tradeable contingent value right (CVR)  worth up to  $4 per share , payable upon achieving certain developmental and commercial milestones. The acquisition is expected to close in the  first quarter of 2025 , subject to standard conditions, including the successful tender of shares representing at least a majority of Poseida’s outstanding stock. As part of the transaction,  Poseida and its employees will join Roche’s Pharmaceuticals Division,  bringing with them expertise in advanced cell therapies. Poseida specia...

Roche Holding AG announced plans to increase manufacturing capacity in China to serve the country’s rapidly growing market, as tensions between the US and China push pharmaceutical companies to split some of their production. The Swiss firm will produce more diagnostic products and increase capacity for medicines in China, with CEO Thomas Schinecker describing the strategy as “China for China” production. "China is simply unbelievably big," Schinecker said, emphasizing that Roche will continue to invest in the country to meet its growing demand. While Roche’s drug substances are produced outside China, the company will focus on the final production stages in China, including fill and finish processes. Schinecker highlighted that geopolitical tensions between the US and China could potentially impact the supply of raw materials essential for pharmaceutical manufacturing, expressing hope that the situation would ease to avoid disruptions for patients. In August, Roch...